Overview
Intellia Therapeutics advances in vivo and ex vivo CRISPR/Cas9 genome editing therapies for genetic diseases. Tailored for modern biology and life science teams.
Key Highlights
- First-in-human in vivo CRISPR therapies targeting transthyretin amyloidosis.
- Collaborations with Regeneron and Novartis on liver and hematology programs.
- Pipeline spanning autoimmune, oncology, and rare diseases.
Ideal For
- Clinicians evaluating emerging genome editing treatments
- Biotech teams partnering on CRISPR technology platforms
- Regulators and payers monitoring CRISPR clinical milestones
Quick Links
- Official site: intelliatx.com
- Add to BioDir collections to track updates and collaborators.